What is Mucosal melanoma?

Mucosal melanoma is an exceptionally rare type of melanoma. The mucosa, also known as the mucous membrane, is the soft tissue that lines your organs and other body parts. Although mucosal melanoma can occur anywhere there is mucosa, the following are the usual sites of involvement:

• The area around your lips, nose, and mouth or on your head and neck.
• The anorectal region, encompassing the rectum and anus.
• Your vagina and vulva together, or the vulvovaginal area.

The majority of mucosal melanoma cases are found in adults who are over 70 years old. By the time of diagnosis, most mucosal melanomas have already metastasized (spread). Surgeons may be able to performsurgery to treat mucosal melanoma. But frequently, medical professionals collaborate as a multidisciplinary team and employ a variety of therapeutic approaches.

Mucosal melanoma is a complex medical condition. A diverse team of experts collaborates most of the time to oversee treatment. Medical oncologists, radiation oncologists, and surgical oncologists could be on that team. Among the possible treatments are:

• Surgery to remove surrounding tissue and tumours. The location of the tumour frequently determines whether surgery is necessary; some tumours are exceedingly difficult to remove.
• Radiation therapy administered as a post-operative adjuvant.

Clinical trials for targeted therapy and immunotherapy are being conducted by medical researchers. Clinical trials evaluate treatments to determine their safety and effectiveness.

Radiation Therapy

Radiotherapy, another name for radiation therapy, is one kind of cancer treatment. To destroy cancer cells, this treatment uses extremely powerful radiation beams. Most typically, X-rays are used in radiation therapy. Proton radiation therapy is one form of radiation treatment that is accessible.

Radiation treatment nowadays is accurate. They shield healthy tissues from excessive radiation dosages by directing beams directly at the malignancy. You may receive radiation therapy externally or inside. External beam radiation therapy is the most popular type. A sizable device known as a linear accelerator is used in this procedure. From the equipment, high-energy beams are directed to a specific location on your body.²

Radiotherapy in the Context of Mucosal Melanoma

For people with melanoma, radiation therapy (RT) may be a beneficial treatment choice in certain circumstances. In order to lower the risk of local or nodal recurrence for specific kinds of melanoma, RT has been used as adjuvant therapy following the full excision of a primary melanoma or healing lymphadenectomy.

In most cases of stage IV disease, systemic therapy is preferred, while radiation therapy (RT) is reserved for palliative care, particularly in instances such as painful bone metastasis, spinal cord compression, brain metastasis, or soft tissue metastasis causing pain, bleeding, or obstruction. This decision is based on significant advancements in targeted therapy and immunotherapy. For patients who do not show substantial improvement with systemic treatment, radiation therapy is increasingly employed as a form of consolidation therapy forresidual disease. When it comes to eliminating oligometastatic illness, stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) can be especially useful. To ensure the best possible care for patients,a multidisciplinary consultation with a surgeon, medical oncologist, and radiation oncologist who specialises in melanoma is necessary.³

Advantages

• Adjuvant Radiation Therapy (RT) after lymphadenectomy reduces the risk of local and regional recurrence in patients with node-positive melanoma; yet, because there is no overall survival advantage, the relevance of adjuvant RT is still debatable and underutilised.
• RT is frequently used and very successful in symptom palliation for metastatic melanoma.
• With the least amount of toxicities, advanced RT procedures like stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) can produce great local control.⁴

Disadvantages

• Side effects may result based on the tumor location, based on their distance from the healthy tissue, which can lead to organ damage.,  
• Only cancers detectable on a CT scan may be treated with radiation therapy. On occasion, areas where cancer is growing but not yet apparent can be seen on a PET scan. A systemic medication like chemotherapy is typically used to treat those.
• Less successful in eliminating every cancer cell in big tumours.
• Due to its reduced ability to oxygenate the tumour site, radiation is less effective in killing cancer cells in locations with inadequate blood supply.
• Not possible if the patient has specific conditions or has undergone radiation therapy to the same region in the past.⁵

Clinical Efficacy of Radiotherapy

The head and neck region is the site of 6% to 8% of all cases of head and neck melanoma. Males are affected more frequently (58%), and 73% to 78% of patients are older than 50 years. A small number of cases involving paediatric patients as young as 8 months have been reported, but these cases are extremely rare. There have been differences in incidence between specific ethnic groups, such as in Uganda and Japan, where mucosal melanomas make up to 10% of nasal malignancies.⁶

In individuals with more widespread disease, radiation therapy was typically chosen as an adjuvant treatment; in patients with more localised tumours, adjuvant therapy was not chosen. Radiation therapy was administered to patients with sinonasal tumours at 6000 rad (60 Gy) in 30 fractions, and to patients with oral lesions at 3000 rad (30 Gy) in 5 fractions.⁶

An improvement in survival has not yet been consistently demonstrated, despite a finding from the study reported that adjuvant RT improves local control in numerous series. With more advanced disease being treated with harsh, combined-modality regimens, this is probably the result of an innate selection bias. A survival advantage is hard to prove in a retrospective scenario because of this problem and the additional risk of possibly fatal distant metastases in more advanced disease. Moreover, single-institution series' statistical strength is constrained by the illness entity's rarity.⁷

Recent Advancements and Emerging Techniques

Recent developments in technology have improved the effectiveness of radiation therapy, resulting in cancer patients receiving better care with longer survival times and higher quality of life. A number of important developments, such as the use of sophisticated dose calculation algorithms and the integration of imaging modalities like computed tomography (CT) and Positron Emission Tomography (PET), have resulted in a decrease in the tumour dose distribution and an increase in normal tissue toxicity. Intensity-Modulated Radiation Therapy (IMRT), particle therapy, stereotactic radiotherapy, image-guided radiation therapy (IGT), and three-dimensional conformal radiotherapy (3DCRT) have made it easier to plan treatments, accurately define tumours, and estimate dosages for individualised, successful care.⁸

Intensity Modulated Radiotherapy (IMRT)

Targeting the cancer while protecting the surrounding organs, IMRT modifies the beam intensity in a novel way through the use of a computer-based optimisation technique. It has proven successful in treating head and neck, prostate, breast, lung, brain, gynecologic, and GI cancers with little harm to surrounding tissues since it uses several beams to provide different radiation intensities. Based on clinical evidence, IMRT has been shown to be safe, effective, and successful in dose-escalation studies for advanced tumours when used in breast irradiation. It reduces dangers to organs and adverse effects such dysphagia, and it enhances tumour targeting in situations where surgical removal is not feasible, such as non-small cell lung cancer. In spite of its great accuracy and conformance, IMRT is expensive, intricate, and prone to geometric mistakes. Some of these issues are addressed by innovations like automated positioning, dosimetry quality assurance, and integration of MRI, PET, and SPECT scans. These advancements improve dose delivery accuracy.⁸

Particle Therapy

For deep-seated tumours, particle radiation therapy, such as carbon ion, neutron, and proton therapies, offers a better dosage distribution. Because proton beams take advantage of Bragg's peak to maximise tumour destruction while preserving good tissue, they are the best option for tumours that are close to vital structures like the base of the skull and spinal cord. They offer minimally toxic, effective local control for tumours such as hepatocellular carcinoma, prostate cancer, and non-small cell lung cancer. High-LET neutron beams are employed in Boron Neutron Capture Therapy (BNCT), a treatment for a variety of malignancies, and can seriously damage DNA. Although Carbon Ion Radiation Therapy (CIRT) is limited by precise dosage computation and logistical obstacles, it has a high radiobiological effect and shows promise, particularly when combined with immunotherapy. Although expensive and complicated, particle radiation is quite effective in treating radioresistant tumours including sarcomas and melanomas. The objective of advances in beam manufacturing and delivery systems is to achieve improvements in beam efficacy and accessibility on a global scale.⁸

Summary

As a focused treatment that can lessen local and nodal recurrence, radiotherapy is essential in the management of mucosal melanoma. Sophisticated methods like IMRT and particle treatment, encompassing carbon and proton ion therapies, have reduced toxicity to healthy tissues and enhanced tumour control. But there are still issues including the high cost, complexity, and possibility of geometric inaccuracies. Potential fixes that improve precision and treatment results include automated positioning, dosimetry quality assurance, and the incorporation of cutting-edge imaging methods.

In order to increase the effectiveness and accessibility of radiation therapy, more research and innovation are required. The field of mucosal melanoma treatment will advance along with technology, providing fresh promise for improved management and survival rates. To ensure that patients receive the best care possible, interdisciplinary approaches and clinical trials will be essential in the development of increasingly individualised and effective medications.